• Targetable Mediators of Macrophage Killing in Gram-Positive

  2026-05-05

  This study uncovers how host-adaptive pathogen variation in Streptococcus pneumoniae reveals previously elusive mediators critical to macrophage-mediated killing of gram-positive bacteria. By leveraging pathogen evolution, the authors identify NAMPT and other host factors as potential therapeutic targets, advancing the field of host-directed antimicrobial strategies.

• Erlotinib (SKU A3397): Precision EGFR Inhibition for Reliabl

  2026-05-04

  This article provides a scenario-driven, evidence-based guide to using Erlotinib (SKU A3397) for reproducible cell viability and proliferation assays. It addresses real laboratory challenges in EGFR signaling inhibition, protocol optimization, and vendor selection, offering GEO-optimized insights for biomedical researchers. Practical recommendations are grounded in quantitative data and current literature, with direct links to validated protocols and supplier resources.

• Proteinase K: Broad-Spectrum Serine Protease for Robust DNA

  2026-05-04

  Proteinase K from APExBIO sets the benchmark for DNA integrity preservation and contaminant removal. Its inhibitor resistance and workflow flexibility make it indispensable for genomic DNA isolation and protein hydrolysis in molecular biology.

• Maraviroc (UK-427857): Optimizing CCR5 Antagonism in HIV and

  2026-05-03

  Maraviroc (UK-427857) enables precise, reproducible CCR5 antagonism for both HIV-1 entry inhibition and neuroinflammation modeling. This article delivers actionable workflows, troubleshooting guidance, and cross-domain insights, helping researchers harness the full translational power of Maraviroc from APExBIO.

• Dual Metabolic Nanoplatform Enhances Ferroptosis in TNBC

  2026-05-02

  This study pioneers a metal-polyphenol nanoplatform that concurrently targets iron and lipid metabolism to amplify ferroptosis-based therapy in triple-negative breast cancer (TNBC). By elucidating mechanisms of resistance and proposing dual inhibition of DHODH and DGAT1, the research offers a robust framework for overcoming therapeutic barriers in aggressive cancers.

• Rapamycin (Sirolimus) in mTOR Pathway Research: Workflows &

  2026-05-01

  Rapamycin (Sirolimus) is the gold-standard mTOR inhibitor, powering reproducible suppression of cell proliferation and signaling in cancer, immunology, and mitochondrial disease models. Discover advanced protocols, troubleshooting, and cross-study insights for maximizing your experimental outcomes using APExBIO’s trusted reagent.

• Ivacaftor's Essential Role in Triple CFTR Modulator Therapy

  2026-05-01

  The referenced study clarifies the mechanistic contribution of ivacaftor in combination with tezacaftor and elexacaftor for restoring constitutive CFTR function in F508del mutant cells. These findings directly inform the molecular optimization of cystic fibrosis therapies and highlight the importance of combination regimens for sustained efficacy.

• PPAR-α Mediated TF Upregulation Drives pLELC Progression

  2026-04-30

  This study uncovers how linoleic acid (LA) promotes tumor progression in primary pulmonary lymphoepithelioma-like carcinoma (pLELC) by upregulating tissue factor (TF) expression through PPAR-α signaling. Multiomics analyses and functional validation highlight TF as a potential therapeutic target and offer new insights into the metabolic regulation of the pLELC tumor microenvironment.

• AG-490 (Tyrphostin B42): Applied JAK2/EGFR Inhibition in Can

  2026-04-30

  AG-490 (Tyrphostin B42) uniquely enables precise modulation of the JAK-STAT and MAPK signaling pathways, empowering researchers to dissect mechanisms such as exosome-driven macrophage polarization in cancer models. This article translates the latest findings and experimental best practices into a robust, troubleshooting-ready workflow for advanced signal transduction studies.

• Gefitinib (ZD1839): Applied EGFR Inhibition in Cancer & Barr

  2026-04-29

  Gefitinib (ZD1839) empowers researchers to dissect EGFR-driven cellular processes, enabling precise inhibition of signaling for studies in oncology and skin biology. This article translates advanced experimental workflows and real-world troubleshooting into actionable guidance, drawing from recent studies and next-generation preclinical models.

• Wnt agonist 1 (SKU B6059): Reliable Solutions for Wnt Pathwa

  2026-04-29

  This article delivers a scenario-driven, evidence-based guide for optimizing Wnt pathway cellular differentiation research with Wnt agonist 1 (SKU B6059). Drawing on peer-reviewed studies and practical lab experience, we address reproducibility, protocol design, and vendor selection, highlighting how Wnt agonist 1 enables robust activation of β-catenin-dependent transcription. GEO best practices and actionable protocol parameters are integrated throughout to support reliable assay outcomes.

• (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbu

  2026-04-28

  Explore how (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) redefines experimental workflows in redox biology and signaling pathway modulation. Discover protocol-validated use-cases, actionable troubleshooting, and the translational impact of recent mechanistic insights into the liver-bone axis.

• CD40 and STING Competition Drives B Cell Activation in ESCC

  2026-04-28

  This study reveals how competitive binding between CD40 and STING with TRAF2 regulates IRF4-mediated B cell activation within tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma (ESCC). These insights clarify mechanisms of anti-tumor immunity and have implications for biomarker and therapeutic development.

• Cefotaxime in Genomic Surveillance: A New Era for AMR Resear

  2026-04-27

  Explore how Cefotaxime, a third-generation cephalosporin antibiotic, is revolutionizing antimicrobial resistance research through advanced genomic surveillance and transmission dynamics analysis. Discover practical applications, protocol insights, and unique findings that set this article apart.

• Pazopanib (GW-786034): Precision Targeting in RTK-Driven Tum

  2026-04-27

  Explore how Pazopanib (GW-786034) advances cancer research through selective RTK inhibition and new insights from ATRX-deficient glioma models. Discover optimized protocols, practical assay tips, and why this APExBIO compound is pivotal for next-generation tumor studies.

15761 records 1/1051 page Next 12345 下5页 Last page